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Abstract Type 1 diabetes (T1D) is considered a disorder
whose pathogenesis is autoimmune in origin, a notion drawn
in large part from studies of human pancreata performed as
far back as the 1960s. While studies of the genetics,
epidemiology, and peripheral immunity in T1D have been
subject to widespread analysis over the ensuing decades,
efforts to understand the disorder through analysis of human
pancreata have been far more limited. We have reviewed the
published literature pertaining to the pathology of the human
pancreas throughout all stages in the natural history of T1D.
This effort uncovered a series of findings that challenge
many dogmas ascribed to T1D and revealed data suggesting
the marked heterogeneity in terms of its pathology. An
improved understanding and appreciation for pancreatic
pathology in T1D could lead to improved disease classifica-
tion, an understanding of why the disorder occurs, and better
therapies for disease prevention and management.
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Type 1 diabetes
The insulin deficiency associated with type 1 diabetes
(T1D) is thought to be due to an autoimmune-mediated
destruction of pancreatic β-cells; this is the result of an
(still) ill-defined combination of genetic susceptibilities
alongside environmental factors [59, 65]. Despite the
availability of exogenous insulin therapy, T1D patients
remain at risk for a number of chronic complications that
result from poorly controlled blood glucose concentrations
[1, 26, 63]. For this reason, as well as other issues of
increased morbidity and mortality, an immense need exists
for studies capable of shedding light onto the pathogenesis
of T1D including an elucidation to the question of how and
why the pancreatic β-cell becomes a target.
Beyond genetic (HLA) susceptibility, the autoimmune
etiology of T1D has primarily been based on the identifi-
cation of islet cell reactive autoantibodies in the serum of
patients with or at genetic risk for T1D [6, 48, 50, 52, 61,
83, 87, 100], as well as lymphocytic infiltrates in the
pancreatic islets of patients who died shortly after disease
onset [12, 17, 21, 22, 28, 29, 46]. Little is known about the
etiological underpinnings for pathogenesis of T1D in
humans, but a number of theories, based on data from
humans and animal models, have been proposed to explain
how β-cell autoimmunity is initiated and eventually,
progresses to a degree of insulin deficiency, which
expresses itself as hyperglycemia. Some of the more popular
theories include molecular mimicry [7] resulting from cross-
reactivity of viral [77, 92] or dietary antigens [3, 55, 57]w i t h
β-cell antigens, gut microflora that drive deleterious immune
responsiveness [15, 25, 80], dysfunctional β-cell antigen
expression in the thymus [19] and pancreatic lymph nodes
[99], among others. With so many etiologies that could
potentially lead to loss of immunological tolerance to β-cell
antigens and subsequent cellular destruction, attention has
recently been directed towards investigations of the human
pancreas in T1D. To be clear, this notion is not a new one
since as mentioned previously, studies of human pancreata
from individuals with diabetes date back many decades.
With this, it is fair to ask the question of what can re-
examination of the literature pertaining to human pancreas
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may not have been evident in the past? Insights gained from
recent epidemiological studies, when combined with histo-
pathology, may provide valuable information regarding the
factors involved in the incidence of this disease, with the
pathologic features either supporting or refuting hypothet-
ical relationships. As but one example, the steady increase
in T1D incidence in most developed countries [68, 74, 82,
86, 89, 90] suggests that new, or more widespread exposure
to environmental agents (dietary, virus), may initiate or
accelerate β-cell autoimmunity. Indeed, worldwide epide-
miological data indicate that the proportion of newly
diagnosed children with genotypes considered at high risk
for T1D are decreasing (i.e., the disease is more often
diagnosed in those who, in previous generations, may not
have been considered as having an exceedingly high
genetic risk for T1D), which as Borchers et al. [11] and
others [24] have pointed out, suggests that environmental
factors are now of increasing importance in the develop-
ment of β-cell autoimmunity. In terms of actual environ-
mental factors that may be driving such processes, there are
no shortage of candidates as increased consumption of
milk, cereals, and meat (among other dietary factors) have
been associated with the increased T1D incidence [67].
Other studies have noted that children who developed T1D
had higher energy intake, disaccharides and sucrose in
particular, and larger body size in the years preceding disease
onset [73]. Taken collectively, these studies support the so-
called “overload hypothesis” proposed by Dahlquist [18],
which suggests that environmental factors which increase
insulin demand will accelerate the β-cell destruction
following the initial triggering of autoimmunity. In an
alternate scenario for this model, heightened insulin secretion
“injures” β-cells, providing the initial trigger (i.e., expression
of autoantigens [16, 33], class I HLA [70], cytokines [23])
that provokes a self-destructive immune response.
As this review discusses the pancreatic pathology of
T1D, it is important to begin by briefly describing previous
attempts to categorize this heterogeneous disease, both with
and without the aid of pancreatic histology. The clinical
diagnosis of T1D is based primarily on a combination of
hyperglycemia, an absolute or severe loss of C-peptide
secretion and dependence on exogenous insulin for survival
[42]. The etiology of this loss of C-peptide secretion and,
presumably, β-cell destruction has been divided into
autoimmune-mediated (i.e., type 1A; based on the presence
of islet cell autoantibodies), as well as idiopathic (type 1B)
diabetes [42]. Currently, islet autoantibodies (e.g., glutamic
acid decarboxylase, insulin, IA-2, zinc transporter) are not
routinely performed in most clinical settings, making it
difficult to differentiate between type 1A and type 1B
diabetes. This fact complicates the interpretation of (already
confusing) past pathologicstudies of what has, overthe years,
been referred to as juvenile diabetes, or insulin-dependent
diabetes. Hence, it is not possible to definitively differentiate
between cases that are true type 1A in origin without
histologicevidenceofautoimmunityfromthosewithtype1B.
The conundrum of evaluating human pancreas
pathology
While the study of pancreata from individuals with T1D
would be expected to provide important clues as to T1D
pathophysiology, limitations in access to research quality
samples are hampered by the very nature of the organ;
namely, to function as a potent digestive tissue. Another
major limitation, however, is access to the earliest stages of
T1D when β-cell loss begins. Since (and fortunately) T1D
is generally not an acutely fatal disease at its diagnosis,
pancreatic tissue samples at clinical onset are not generally
available nor can biopsy be safely performed without a
great risk for pancreatitis. In addition to the inaccessibility
of the pancreas, T1D is a difficult disease to investigate due
to a long, clinically silent period that precedes disease onset
(i.e., symptomatic hyperglycemia), during which time,
lymphocytes traffic to the islets and mediate the progressive
destruction of β-cells. Elucidating the early events that
occur prior to, and presumably stimulate this self-
destructive process, is therefore an important goal for
evaluating human pancreatic specimens to identify disease
initiation and progression. With longer disease duration,
evidence of active β-cell autoimmunity (i.e., insulitis)
appears to become increasingly rare. In addition to these
T1D-specific caveats, the very nature of cadaveric histopa-
thology studies in which pathologic information is only
available for a single time point makes it difficult to
understand the pattern and rate of β-cell loss or, alternately,
β-cell regeneration from one individual to another. Finally,
unknown chronic effects of fluctuating blood glucose and
insulin concentrations on β-cell survival and autoimmunity
complicate interpretation of pancreatic histopathology. These
multiple factors obscure the interpretation from human
pancreatic specimens but nevertheless, such are the primary
means for elucidating T1D pathogenesis in humans.
Study descriptions (case reports and beyond)
To initiate our presentation of the pancreatic pathology of
human T1D, patient information was compiled from six
T1D histopathology studies (Fig. 1) and categorized by the
presence or absence of β-cells or insulitis in patients who
underwent either a short (Tables 1 and 2) or long disease
duration (Tables 3 and 4), all as defined in the respective
studies [17, 21, 22, 28, 29, 46]. These studies were chosen
30 Semin Immunopathol (2011) 33:29–43because data on age, disease duration, and islet pathology
(i.e., β-cells, insulitis) were available for each individual
case. Pancreatic pathology prior to disease onset has also
been described in a small number (n=6) of autoantibody-
positive nondiabetic individuals drawn from three addition-
al studies (Fig. 1)[ 31, 40, 93].
From a historical perspective, the original work of Gepts
[28] is considered by most to represent the seminal work
with examination of autopsy pancreatic specimens from 54
diabetic patients who developed the disease prior to age of
31 years. These cases were obtained from hospitals in
Brussels, Belgium and the USA (Philadelphia, Boston,
Winston-Salem, Keene). Twenty-two cases were considered
“acute”, since duration from first appearance of diabetic
symptoms (i.e., polydipsia, weight loss, polyuria) to death
was less than 6 months. The remaining 32 cases were
considered “chronic” as disease duration ranged from 2 to
37 years. In addition to these studies of Gepts, Junker et al.
[46] examined autopsy material from 11 patients with
reported diabetes of ages 30 years or less who also resided
in Denmark. The first appearance of diabetic symptoms in
each of these Danish patients occurred within 2 months of
death, and none of the patients received insulin therapy
prior to admission; however, all received insulin at hospital
Table 1 β-cells in short duration type 1 diabetic patients. Number, age, disease duration, and onset age of patients with (β-cell+) and without
(β-cell−) β-cells in various studies
Reference Duration (years)
(mean±SEM, range)
β-cell+ cases β-cell− cases
N (%) Age
(years)
Duration
(years)
Onset age
(years)
N (%) Age
(years)
Duration
(years)
Onset age
(years)
[28] 0.10±0.03 (1–180 days) 16 (94) 12.6±2.1 0.06±0.02 12.5±2.1 1 (6) 3.0 0.08 2.9
[46] 0.06±0.02 (7–56 days) 1 (9) 29.7 0.06 29.6 10 (91) 14.0±3.4 0.06±0.02 13.9±3.4
[21] 0.10±0.02 (1–84 days) 9 (100) 5.6±1.3 0.10±0.02 5.5±1.3 0 (0) –– –
[22] 0.10±0.02 (7–270 days) 47
a (100) 9.2±0.8 0.10±0.02 9.12±0.75 0 (0) –– –
[29] 0.08±0.02 (1–90 days) 14 (87) 12.9±3.1 0.08±0.02 12.8±3.1 2 (13) 8.0±7.0 0.06±0.02 7.9±7.0
[17] 0.92±0.38 (0–3 years) 9 (100) 24.3±3.4 0.92±0.38 23.4±3.4 0 (0) –– –
aProportion of patients with β-cells is biased since information was available only for individuals with insulitis in this study
Fig. 1 Comparison of histopathological studies of type 1 diabetes by
stage of disease course. The region in blue corresponds to the narrow
range of disease duration (<2 months) that is represented across all six
studies indicated at right. The region in gray corresponds to the period
prior to disease onset (pre-clinical phase) and lists the three studies
that examined pancreata from nondiabetic individuals with islet
autoantibodies
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was related to coma most likely secondary to diabetic
ketoacidosis (i.e., hypopotassemia, cerebral edema, ketoa-
cidosis). Later, Gepts and De Mey [29] studied pancreatic
specimens, obtained from hospitals in Brussels, Belgium
and the USA, from 58 patients with diabetes under 40 years
of age who were divided into three groups based on disease
duration: 1–90 days (n=16), 0.5–10 years (n=14), and
greater than 10 years (n=28). Foulis and Stewart [21]
examined pancreata from 11 patients with diabetes,
obtained from the Royal Hospital for Sick Children in
Glasgow, UK. Of these 11 patients, 9 had diabetes
symptoms for 1–12 weeks and died within 24 h of clinical
diagnosis, while the other two patients had diabetes for 2
and 6 years and received injections of insulin to control
symptoms. Death in all patients, with the exception of one
patient with a 2-year diabetes duration who died of lobar
pneumonia, was caused by complications associated with
ketoacidotic coma. Later, Foulis et al. [22] studied pancreatic
autopsy specimens from 119 patients with diabetes under
20 years of age from Scotland, Wales, and England. Among
the 95 patients for which duration of diabetes was known,
disease duration was less than a year for 60 patients and 1–
14 years in the remaining 35. Complications of ketoacidosis
was the cause of death among all recent-onset cases in this
series except one, and the most common cause of death
among the long duration cases. Finally and far more recently,
Butler et al. [17] examined pancreatic autopsy specimens
from patients diagnosed with diabetes and with a disease
duration of less than 3 years, who died of ketoacidosis.
Pathology
Islet morphology
Gepts described the appearance of islets from individuals
with juvenile diabetes mellitus, classifying them into one of
three categories [28]. So-called “type I islets” were
distinguished primarily by their irregular outline and
continuity between β-cells and the surrounding acinar
tissue, based on staining by Gomori's chromium hematox-
ylin phloxine. Most islets of this type are small in size,
though variable, with thin cords of endocrine cells within a
fibrous stroma. The cells that comprise these type I islets
were also small, having small nuclei containing dense
chromatin and cytoplasm that was not abundant and did not
show evidence of granulation. These were considered by
Table 2 Insulitis in short duration type 1 diabetic patients. Number, age, disease duration, and onset age of patients with (insulitis+) and without
(insulitis−) insulitis in various studies
Reference Duration (years)
(mean±SEM, range)
Insulitis+ cases (mean±SEM) Insulitis− cases (mean±SEM)
N (%) Age
(years)
Duration
(years)
Onset age
(years)
N (%) Age
(years)
Duration
(years)
Onset age
(years)
[28] 0.10±0.03 (1–180 days) 15 (68) 8.0±1.6 0.09±0.03 7.9±1.6 7 (32) 17.2±3.3 0.12±0.04 17.1±3.3
[46] 0.06±0.02 (7–56 days) 6 (54) 8.6±3.8 0.07±0.02 8.5±3.8 5 (46) 23.6±3.3 0.05±0.03 23.6±3.3
[21] 0.10±0.02 (1–84 days) 8 (89) 4.9±1.2 0.10±0.02 4.8±1.2 1 (11) 11.0 0.04 10.96
[22] <1 year
a 47 (78) 9.2±0.8 0.10±0.02 9.1±0.8 13 (22)
aa a
[29] 0.08±0.02 (1–90 days) 11 (68) 8.5±3.4 0.06±0.02 8.4±3.4 5 (32) 20.6±2.8 0.12±0.05 20.5±2.8
[17] 0.92±0.38 (0–3 years) 5 (55) 21.4±5.4 0.81±0.49 20.6±5.4 4 (45) 28.0±3.7 1.07±0.68 26.9±3.7
aAge, duration, and onset age information were not available for patients without insulitis in this study
Table 3 β-cells in long duration type 1 diabetic patients. Number, age, disease duration, and onset age of patients with (β-cell+) and without
(β-cell-) β-cells in various studies
Reference Duration (years)
(mean±SEM, range)
β-cell+ cases β-cell− cases
N (%) Age
(years)
Duration
(years)
Onset age
(years)
N (%) Age
(years)
Duration
(years)
Onset age
(years)
[28] 17.7±1.9 (2–37 years) 4 (33) 35.5±3.9 16.0±3.6 19.5±5.1 8 (67) 32.4±3.2 19.8±3.3 12.6±2.7
[21] 4.0±2.0 (2–6 years) 2 (100) 10.0±1.0 4.0±2.0 6.0±1.0 0 (0) –––
[22]( 1 –14 years) 8 (23) 13.3±2.1 3.6±1.0 9.7±2.0 27 (77)
aaa
[29] 6.3±0.8 (0.5–10 years) 7 (50) 24.9±5.1 5.6±1.4 19.2±4.2 7 (50) 16.3±2.1 7.0±0.7 9.3±1.7
[29] 21.0±1.0 (12–37 years) 5 (18) 37.0±2.7 20.0±1.1 17.0±3.1 23 (82) 33.5±1.2 21.2±1.2 12.3±1.2
aAge, duration, and onset age information were not available for patients without β-cells in this study
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diabetics in general, and accounted for the vast majority of
islets found in chronic cases [28]. Type II islets were more
clearly defined by Gomori's stain in the acinar tissue than
type I islets [28]. While type II islets were also variable in
size like type I islets, type II islets tended to be large.
Likewise, cells within these islets were large in size, with
large nuclei and unlike type I islets; their cytoplasm was
abundant, indicating hypertrophy. While the cytoplasm was
often free of granules like type I islets, some β-cells could
be found with granulations, some irregularly shaped.
Variable numbers of type II islets were found in acute
cases only [28]. Finally, type III islets were considered to
resemble normal islets and have variable proportions of β-
cells that were marginally hypertrophic and appeared
degranulated to differing degrees. These types of islets
were infrequent in both acute and chronic cases [28].
Pathologic features of short disease duration
β-cell survival The great majority (i.e., 87–100%) of
recent-onset cases with diabetes were noted to contain
insulin-positive β-cells, as reported in five [17, 21, 22, 28,
29] of the six studies (Table 1). Junker et al. [46] reported
finding only one case among 11 studied with β-cells
containing insulin granules. However, as Gepts and De
Mey [29] pointed out, this inability to identify β-cell
granules, especially in cases of such short duration (i.e., 1–
8 weeks), may have been due to the relative insensitivity of
the Gomori staining method in comparison to more modern
immunohistochemical techniques. In contrast, Gepts
reported the observation of β-cells in 16 out of 17 acute
cases. Onset age of the single case without any detectable
β-cells was much younger (2.9 years) in comparison to
those that had β-cells (12.5 years). Similarly, Gepts and De
Mey reported that β-cells were observed in 14 out of 16
short duration cases, with the onset age in the two cases
devoid of detectable β-cells occurring somewhat earlier
(7.9 years) than those cases with β-cells (12.8 years).
Lobular distribution of insulin-containing islets In those
patients with insulin-containing islets remaining, although
greatly reduced in proportion, a distinct lobular distribution
of these islets has consistently been reported by several
studies [17, 21, 22, 28, 29]. In other words, multiple
insulin-positive islets tend to be found within one or a few
lobules, as opposed to scattered throughout all acinar
regions. This can result in an adjacent lobule being entirely
deficient of insulin-positive islets. The biological signifi-
cance of this lobular distribution is unclear, but may have
implications for T1D pathogenesis such as lobular differ-
ences in islet autoreactivity, blood supply to and/or within
lobules, trafficking of autoreactive T cells, and other factors
may be of significance. However, it must also be clearly
defined whether the pancreatic uncinate lobe was exam-
ined, since that lobe contains islets with a much lower
proportion of β-cells within islets [30].
Insulitis The term insulitis was coined by Von Meyenburg in
1940 to describe the mononuclear inflammatory infiltrate
surrounding and within the islets of individuals with juvenile
diabetes [91]. The insulitis lesion represents the predominant
histopathological feature of T1D as it is frequently observed
in pancreata from T1D patients after a short disease course
(Fig. 2)[ 12, 17, 21, 22, 28, 29, 46]. The presence of insulitis
is, with near uniformity, associated with a marked reduction
in the number of insulin-containing islets and a dependence
on exogenous insulin. Therefore, it is thought to represent a
process whereby inflammatory cells directly cause the
destruction and/or dysfunction of β-cells. For these reasons,
much effort has been focused on identifying the cell types
involved, as well as the various stimuli that provoke
progression of insulitis to understand pathogenesis as well
as to identify potential therapies for this disease.
Insulitis was found in the majority of recent-onset cases
(54–89%) in the six studies [17, 21, 22, 28, 29, 46] shown
in Table 2. Based on a comparison of these studies, the
presence of insulitis appeared to be more dependent on
earlier onset age than the variable of disease duration. In the
Table 4 Insulitis in long duration type 1 diabetic patients. Number, age, disease duration, and onset age of patients with (insulitis+) and without
(insulitis-) insulitis in various studies
Reference Duration (years)
(mean±SEM, range)
Insulitis+ cases (mean±SEM) Insulitis− cases (mean±SEM)
N (%) Age
(years)
Duration
(years)
Onset age
(years)
N (%) Age
(years)
Duration
(years)
Onset age
(years)
[28] 17.7±1.9 (2–37 years) 0 (0) ––– 18 (100) 30.2±2.1 17.7±1.9 12.5±1.9
[21] 4.0±2.0 (2–6 years) 0 (0) ––– 2 (100) 10.0±1.0 4.0±2.0 6.0±1.0
[22]( 1 –14 years) 3 (9) 13.0±3.1 3.2±1.4 9.8±3.9 32 (91) 13.3±2.1
a 3.6±1.0
a 9.7±2.0
a
[29] 6.3±0.8 (0.5–10 years) 0 (0) ––– 14 (100) 20.6±2.9 6.3±0.8 14.2±2.5
[29] 21.0±1.0 (12–37 years) 0 (0) ––– 28 (100) 34.1±1.1 21.0±1.0 13.1±1.2
aOf the 32 insulitis-negative cases, age, duration, and onset age information were available only for 5 insulin-positive cases in this study
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without insulitis was 17.1 years (n=7), while among those
with insulitis, it was 7.9 years of age (n=15). Similarly, in
the study by Junker et al. [46] there was no insulitis
observed in cases with an onset of 23.6 years of age (n=5)
in comparison to cases with insulitis, in which the onset age
was 8.5 years of age (n=6). This relationship was also
shared in the study by Gepts and De Mey [29]. The one
exception to this relationship between insulitis and earlier
onset age was seen in the Butler study, where in which
onset age was very similar between those cases with and
without insulitis [17]. This may have been due to the older
patient population or the longer disease duration (<3 years),
which was longer in cases without insulitis, compared with
the studies of patients of shorter duration. There is the
possibility that some of the cases in these studies, especially
those of late onset age, were of the idiopathic, non-
autoimmune, subtype of T1D or even type 2 diabetes which
would certainly alter the proportion of insulin+insulitis cases.
Immune cells of the insulitis lesion Bottazzo et al. reported
that lymphocytes were the primary cell type occupying the
insulitis lesions of a 12-year-old girl who died within 24 h
of diagnosis [12]. More specifically, the lymphocytes were
considered predominately cytotoxic/suppressor Tcells, with
fewer numbers of helper T cells and natural killer (NK)
cells. The majority of T cells within and around the islets
were immunoreactive for HLA-DR. Class I HLA expres-
sion was clearly increased compared with normal tissues, in
islets, and interestingly, this occurred whether or not an islet
was affected by insulitis. β-cells, identified by C-peptide
positivity, were immunoreactive for HLA-DR, but glucagon
+ and somatostatin+ cells were not. Capillaries within and
surrounding islets were stained for HLA-DR as well. Foulis
et al. described a peripheral infiltrate of cells immunoreac-
tive for T200 leukocyte common antigen, which labels all
cells of hematopoietic origin, in early insulitis and a more
extensive T200
+ cell infiltrate throughout the islets with
advanced insulitis [22].
Itoh et al. examined pancreata from 18 newly diagnosed
patients with T1D for expression of the intercellular adhesion
molecule-1 (ICAM-1) and MHC classes I and II, as well as
immunecelltypes presentininsulitis lesions[41]. MHC class
I hyperexpression was observed in islets and endothelial
cells from nine patients, and MHC class II hyperexpression
was observed in endothelial cells of those same patients. In
the eight patients with insulitis, CD8
+ cells predominated
along with macrophages and lesser numbers of CD4
+ cells
and B cells. Seven of the eight patients with insulitis showed
hyperexpression of MHC class I. Expression of the adhesion
molecule ICAM-1 was increased in endothelial cells from
two of nine patients with MHC class I hyperexpression.
Their data indicated that adhesion molecule expression was
not associated with insulitis but confirmed that CD8
+ cells
were associated with MHC class I hyperexpression in
insulitis lesions from new-onset T1D patients [41].
Insulitis preferentially affects insulin-containing islets In
most studies where insulitis was found, islets with insulin-
containing β-cells were much more frequently affected than
insulin-deficient islets. Specifically, Foulis and Stewart
reported that 18% of insulin-containing versus 1% of
insulin-deficient islets were affected by insulitis in eight
recent-onset children who died within 24 h of initial
presentation [21]. Foulis et al. observed a similar frequency
with 23% of insulin-containing islets and 1% of insulin-
deficient islets affected among recent-onset patients [22]. In
the aforementioned case report by Bottazzo et al., insulitis
affected 24% of the islets examined [12]. Additionally, the
number of insulin-containing islets found and the percent-
age that was affected by insulitis were 2 (100%) in the
pancreas head, 30 (43%) in the body, 53 (28%) in the tail,
and 85 (35%) in the pancreas as a whole. The frequency
and distribution of insulitis were described as “patchy” (i.e.,
heterogeneous), in that all insulin-containing islets were not
uniformly affected. The apparent preference towards
insulin-containing islets could indicate that the inflamma-
tory lesion is targeted against the β-cells and not islets in
general.
Fig. 2 Insulin-containing islet affected by insulitis in recent onset
patient with type 1 diabetes. Pancreatic section, from nPOD, of a 12-
year old recent-onset (1 year duration) T1D patient stained with
antiserum against glucagon (red) and CD3 (brown). Inset image, serial
section of the same islet stained with antiserum against insulin (red)
and Ki-67 (brown). Insulitis with CD3
+ T cells is observed around
periphery and within the islet
34 Semin Immunopathol (2011) 33:29–43This relationship between insulin-containing islets and
insulitis was further investigated by Willcox et al. [96], who
described the association between the degree of islet β-cell
loss and the type and number of immune cells in infiltrates
from 29 recent-onset T1D patients, which was part of the
larger cohort examined by Foulis et al. [22]. The mean age
of the cases was 11.7 years with a duration of less than
18 months for 24 cases and unknown in the remaining
three. At all stages of β-cell decline, CD8
+ T cells were the
predominant cell type. In early insulitis, i.e., when a large
percentage of islet insulin area still remained, CD68
+
macrophages were present in relatively larger numbers.
CD20
+ cells, in contrast, were present in low numbers in
early insulitis but increased as β-cell loss progressed. At all
stages, CD138
+ plasma cells were rare. CD4
+ T cells were
present at all stages of β-cell decline in similar numbers,
though far less than CD8
+ and CD68
+ cells, regardless of
the degree of insulin area. Interestingly, FoxP3
+ regulatory
T cells were only found in islets from a single patient.
These data indicate that CD8
+ T cells and CD68
+ macro-
phages are recruited early to the insulitis lesion and could
contribute to β-cell degeneration. This immune-mediated
process could progressively bring greater numbers of
cytotoxic CD8
+ cells to the islet until all β-cells, and the
auto-antigen(s) driving this process, have been eliminated.
After this stage, insulitis is no longer observed.
Insulitis and insulin secretion A number of studies in
animals [5, 13, 75, 85] and humans [10, 69] have suggested
that β-cell autoimmunity is dependent on, or amplified by,
insulin secretion. Do any of the histopathological data
support this hypothesis? The data described above indicate
that insulin-containing islets are preferentially targeted by
lymphocytes but do not reveal whether or not insulin-
secreting islets are the true targets. Foulis and Stewart noted
that insulin-containing islets, even those affected by
insulitis, were surrounded by normal, as opposed to
atrophic, acinar tissue [21]. This indirectly suggests that
insulitis-affected islets are actively secreting insulin and
that insulin secretion, or metabolic functions associated
with insulin secretion, may play a role in the attraction of
antigen-presenting cells (APCs) and/or lymphocytes based
on data from mouse studies (discussed below). The fact that
diabetic ketoacidosis contributed to death in a large number
of these cases presents a significant obstacle to linking
heightened insulin secretion, or some function associated
with it such as expression of HLA class I [12] or IAPP [70],
to β-cell autoimmunity since ketoacidosis implies systemic
insulin levels are sufficiently reduced to promote insulin
secretion and, consequently, insulitis in these cases. These
questions may be better addressed in animal models
where insulin therapy and glycemia can be more tightly
regulated.
Insulitis and β-cell hyperplasia/hypertrophy Several stud-
ies [21, 22, 28, 29] reported β-cell hypertrophy in pancreata
from T1D patients of short duration. As mentioned above, a
general feature of type II islets that Gepts described is the
presence of hypertrophic β-cells with nuclear hypertrophy
[28]. Additionally, some cases had type II islets containing
β-cells with irregularly shaped nuclei that had greater
affinity for hematoxylin. The cytoplasmic granulations that
Gepts observed in some of these large β-cells [28] were
previously described by Weichselbaum, and are referred to
as “Körnchen” [94]. These structures appeared to be rich in
ribonucleic acids based on their loss of affinity for toluidine
blue after sections were subjected to ribonuclease digestion.
Gepts and De Mey reported routinely finding enlarged β-
cells with large nuclei and cytoplasm containing many
Körnchen [29]. Foulis and Stewart found that many of the
large islets observed in recent-onset cases contained
hypertrophic β-cells and some had evidence of polyploidy
[21]. Foulis et al. described islet hyperplasia with polyploid
β-cells in some of the recent-onset cases they examined
[22]. Taken together, these findings suggest that β-cells are
in a hyperactive state during the period immediately
following disease onset.
Several studies have reported that islets are larger in size
in pancreata from T1D patients of short duration [12, 21,
28, 46]. Gepts reported a proportionally greater number of
medium and large size islets in pancreata from young
diabetics after a short disease duration compared with age-
matched controls [28]. Of these acute cases described by
Gepts, 15 out of 22 (68%) had insulitis. Interestingly, it was
also reported that type II islets, which tended to be large in
size, were frequently affected by insulitis and observed in
77% of the short duration cases but none of the long
duration cases [28]. Similarly, Foulis and Stewart reported
that eight out of nine recent-onset subjects (2–12 years of
age) had islets that were larger than normal, and islets
affected by insulitis were also found in eight out of nine
subjects [21]. The frequency of normal versus large islets
that were affected by insulitis was however not quantified
in either of these studies. Islet hypertrophy was also
reported by Junker et al. in a few of the 11 recent-onset
cases examined, however it cannot be ruled out that some
of these cases, especially those that were older (25–30 years
of age) and showed no signs of insulitis, may have had type
2 diabetes. Foulis et al. reported finding hyperplastic islets
unaffected by insulitis that contained polyploid β-cells [22].
Bottazzo et al. also reported finding a few hypertrophied
islets in the pancreas from a single recent-onset case [12].
The most straightforward explanation for these findings
is that declining β-cell numbers occurring around the time
of onset induces a compensatory increase in β-cell function
(secretory capacity) and mass [95], although as far back as
1965 Gepts suspected that it was unlikely that the apparent
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for decreased β-cell mass [28]. An alternate explanation is
that dysfunctional glucose-stimulated insulin secretion in
individuals susceptible to develop T1D promotes β-cell
hypertrophy or hyperplasia which then, through an un-
known mechanism, leads to autoimmunity. This can be
indirectly drawn from two studies, one in which it was
demonstrated that glucose sensitivity was impaired in
relatives of T1D patients that progressed to disease [20],
and another that reported a decrease in ICA titers, despite
no change in progression to disease, in a small group of
nondiabetic relatives of T1D patients that were treated with
prophylactic insulin [76].
Insulitis in autoimmune vs. fulminant T1D Fulminant T1D
is a subtype of idiopathic (type 1B) diabetes characterized
by rapid onset of symptoms of hyperglycemia, absence of
autoantibodies, and flu-like symptoms that often occur
before disease onset [38, 39]. Hanafusa and Imagawa
examined pancreatic samples from patients that presented
clinically as autoimmune (biopsy samples obtained for
gastric cancer) or fulminant (biopsy and autopsy) T1D [34].
β-cells were reported to be markedly decreased in patients
with autoimmune T1D without a significant change in α-
cell numbers. As found by others, islet lymphocytic
infiltrates consisted primarily of CD8
+ T cells with fewer
numbers of macrophages and dendritic cells. Expression of
MHC class I was increased in all islet cells, Fas expression
was evident mostly on β-cells, and infiltrating lymphocytes
expressed Fas ligand. In patients with fulminant T1D, in
contrast, β-cells were almost entirely gone, and α-cell
numbers were significantly decreased. Insulitis, consisting
primarily of macrophages and lesser numbers of T cells,
was only observed in patients in whom disease duration
was less than a month. Lymphocytic infiltrates in the
remaining patients with longer disease duration were
restricted to the exocrine pancreas. MHC class I hyper-
expression was not observed in islet cells and Fas and Fas
ligand expression were not observed in islet cells and
lymphocytes, respectively. The authors conclude that β-cell
death in autoimmune T1D is attributed to a long duration
autoimmune process compared to fulminant T1D in which
β-cell death proceeds quickly, possibly caused by viral
infection [34].
β-cell replication and apoptosis Characterization of β-cell
replication and apoptosis rates in T1D is of great
importance in understanding mechanisms of disease and
potential therapies. These rates identify whether or not the
response to the inflammatory microenvironment and/or
metabolic demand is one of regeneration (replication) or
injury (apoptosis), as well as the window of time in which
these responses are occurring. In order to assess β-cell
replication rates, Butler et al. stained sections of pancreatic
autopsy samples from nine new-onset T1D cases for insulin
and Ki67, a cell cycle protein expressed in all stages except
resting (G0), and found no differences in the number of
Ki67-positive β-cells compared to those in nondiabetic
control cases [17]. Apoptosis was also measured in these
samples by staining for insulin and TUNEL (terminal
deoxynucleotidyl transferase dUTP neck end labeling).
There was a significant increase in the frequency of
TUNEL-positive β-cells in T1D cases compared to con-
trols. As the authors noted, all the T1D cases in this study
died of diabetic ketoacidosis and five of the nine contained
islets affected by insulitis, making it difficult to identify
whether these findings are representative of β-cells exposed
to the inflammatory milieu found in recent-onset T1D
pancreata or the systemic toxicity imposed by ketoacidosis
[17]. Regardless, their data confirm that β-cell proliferative
capacity was not able to balance destructive processes and
indeed was not changed from normal levels.
Pathologic features of long disease duration
β-cell survival The four studies [21, 22, 28, 29]t h a t
included pancreatic specimens from long duration T1D
patients reported a surprisingly high percentage (18–100%)
of cases with β-cells remaining compared to patients with
acute onset (Table 3). This would indicate that the loss seen
in patients with young onset or with acute onset is able to
rebound or perhaps some of these patients had a clinical
course more likely due to type 2 diabetes. This would
certainly be a higher possibility for those cases diagnosed
several decades ago. The presence of β-cells in long
duration cases appears more associated with a later onset
age than disease duration since, within two of these studies
[28, 29], durations were comparable, but onset age tended
to be later among those with β-cells. One possible
explanation for this finding, if truly reflective of T1D, is
that a greater percentage of β-cell mass remains at clinical
onset when that occurs in late adolescence/early adulthood
versus childhood because of the age-dependent increase in
the ratio of insulin demand (i.e., body weight): insulin
production capacity (i.e., β-cell mass) [49]. In other words,
β-cell mass increases, albeit slowly, along with the increase
in body weight during childhood and adolescence; whereas
in early adulthood, β-cell mass has already plateaued
despite the continued increase in body weight [66]. This
translates into a very different tipping point, in terms of the
β-cell mass loss, required to precipitate hyperglycemia in
late versus young onset.
Insulitis Insulitis appears rare among the long duration
cases, an example being the study by Foulis et al. [22], in
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(Table 4). The reason that these three cases had insulitis is
not clear since the age, duration, and age of onset were
essentially identical to the cases in this study that had no
insulitis. The relative absence of islets affected by
insulitis after a long disease course (Table 4), despite
the presence of β-cells (Table 2)i nm a n yo ft h e s ep a t i e n t s ,
may be due to the suppression of endogenous insulin
secretion (β- c e l lr e s t[ 14]) by long-term insulin therapy
[4]. Alternatively, some of these cases with remaining β-
cells after a long disease course may have been insulin-
requiring type 2 diabetics as it is difficult, still today and
more so in the past, to retrospectively assign a T1D or type
2 diabetes diagnosis based on limited clinical information
such as autoantibody status, HLA genotype, and C-peptide
levels.
Pattern A and pattern B histopathology T1D is, without
question, an incredibly heterogeneous clinical disease with
variations in autoantibody status, C-peptide level, HLA,
onset age, ethnicity, and rate of progression. Gianani et al.
evaluated pancreatic specimens from 20 cadaveric organ
donors with childhood-onset long duration (mean duration
14 years) T1D in order to identify if there is any
relationship between pathologic findings and the C-
peptide and autoantibody status of the donors [32]. Among
the 20 cases, only six had insulin-containing islets. Three
were designated as having the typical pattern of autoim-
mune T1D (pattern A) with the majority of islets insulin-
deficient. The other three patients displayed a very different
pattern with all islets having β-cells though reduced islet
insulin area (so-called pattern B). Additionally, class I HLA
expression was detected in β-cells of donors displaying
histopathology pattern A as well as survivin expression, an
apoptosis inhibitor that is expressed in human islets during
development fetal [56] and in patients with pancreatitis
[35]. Neither class I HLA nor survivin expression was
detected in β-cells from pattern B donors [32]. Two of the
three donors with pattern A maintained minimal C-peptide
secretion (both 0.06 nmol/l), one donor after 20-year
disease duration, and two of the three were double positive
for autoantibodies (i.e., autoantibodies against ICA512, IA-
2ic; ICA512, ZnT8). Among the three donors exhibiting
pattern B, two maintained C-peptide secretion (7.32,
0.67 nmol/l), and all were autoantibody-negative [32].
Interestingly, insulitis was found in only two of the 20
donors, both pattern A and double positive for autoanti-
bodies. These data suggested that insulin deficiency can
result from two distinct etiologies, one autoimmune in
origin and one presumably due to β-cell dysfunction.
Another explanation for these findings is that both type A
and type B have the same etiology, β-cell dysfunction, and
the severity of dysfunction combined with an individual’s
HLA susceptibility determine if there is an immune
response directed against the β-cell.
Pre-clinical pathology
A wealth of information about the early stages of T1D
pathogenesis, particularly the antigen specificity of lym-
phocyte populations, could be gained by studying pancreata
from individuals at risk for developing T1D yet before
clinical onset. Wagner et al. examined pancreata from three
nondiabetic patients with autoimmune polyendocrine syn-
drome that were positive for islet cell autoantibodies (ICA)
and glutamic acid decarboxylase autoantibodies (GADA)
[93]. In two of the patients, islet morphology and insulin
content appeared normal, and the third had slightly reduced
insulin content possibly related to the longer postmortem
duration. There was no evidence of insulitis, i.e., T cell, B
cell, or macrophage infiltration, no HLA class I or class II
expression, and no immunoglobulin or complement depo-
sition in the three cases [93].
Gianani et al. screened a population of 112 organ donors
for autoantibodies to IA-2 (IA2A), GAD, and insulin (IAA)
[31]. Three subjects were identified as positive, one for
IA2A, one for GADA, and one for both IA2A and GADA.
The pancreas of the IA2A-positive 47-year-old male donor
was available for further study and exhibited fibrosis as was
also found in autoantibody-negative donors. This patient
also had large numbers of small- and medium-sized islets
that were associated with ducts. Glucagon- and insulin-
positive cells were seen closely associated with ductal
epithelium, and some ducts exhibited cells positive for both
CK-19 (i.e., a ductal marker) and chromogranin (i.e., an
endocrine marker). The number of CD45
+ leukocytes in the
IA2A-positive individual was not statistically greater than
in controls [31]. Despite the lack of any evidence for
insulitis in the IA2A-positive donor, the apparent neo-
genesis of endocrine cells and islets from precursors within
the ductal epithelium is a striking finding that may suggest
the possibility that regeneration of endocrine mass [88],
prompted by an unknown environmental stimulus or
genetic defect, precedes the development of β-cell autoim-
munity.
In't Veld et al. screened a large population (n=1,507) of
adult organ donors for ICA, GADA, IA2A, and IAA [40].
Pancreatic biopsies (∼0.5 cm
3) from 62 autoantibody-
positive donors were examined, and insulitis was found in
two donors, who were both positive for ICA, GADA, and
IA2A and the HLA-DQ susceptibility genotype. In one
case, 9% of islets (5 of 58 islets) were affected by either
peri- or central insulitis including one insulin-negative islet.
In the second case, 3% of islets (27 of 917 islets) were
affected by insulitis, which were all insulin-containing, but
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unaffected by insulitis. The infiltrate in both cases consisted
largely of CD3
+/CD8
+ T cells and CD68
+ macrophages
with few CD20
+ B cells and CD3
+/CD4
+ T cells. The β-
cell area was unchanged in the cases with insulitis
compared with control cases. Interestingly, one quadruple
autoantibody-positive donor with insulitis exhibited Ki67
+
β-cells in many of the infiltrated islets, which could either
represent a proliferative response to the stimuli imposed by
the infiltrate or, alternatively, the stimulus for the infiltra-
tion itself.
Comparison of human and NOD insulitis
The non-obese diabetic (NOD) mouse represents the most
valuable animal model for human T1D research [37, 47, 51,
71, 84, 97, 98]. The NOD model replicates the age range in
which human diabetes incidence occurs, corresponding to
adolescence in humans [54] and most importantly, insulitis
is the hallmark feature in the destruction of beta cells [62].
It is important to compare and contrast the histopathology
of the insulitis lesion in humans and NOD mice since the
mouse is so highly utilized in studies aimed at understand-
ing human T1D pathogenesis as well as translation of
potential therapies to humans. This comparison is obviously
complicated by the scarcity of human data pertaining to the
pancreatic pathology prior to disease onset and the inability
to accurately predict time-to-onset in individuals at risk
(HLA, autoantibodies) of developing T1D. This shortcom-
ing makes the NOD mouse a particularly useful animal
model for investigating processes leading up to disease
onset, possibly reflective of events occurring in humans.
The earliest evidence of islet-associated inflammation in
the NOD mouse, stage I, is identified by swelling of blood
vessels adjacent to islets that occurs at about 3 weeks of age
in female mice [43]( T a b l e5). Stage II occurs at
approximately 7 weeks, and is characterized by increased
numbers of ER-MP23
+ dendritic-like cells and MOMA-1
+
or BM8
+ macrophages that begin to appear at the islet
periphery near blood vessels. At this stage, some islets
already display infiltrating BM8
+ macrophages. At stage
III, CD4
+ and CD8
+ T cells can be seen moving out of
blood vessels near islets. Most lymphocyte aggregates also
contain some number of B cells and both ER-MP23
+ and
BM8
+ cells with MOMA-1
+ cells situated at the outer
border. Stage IV lesions are those that completely surround
the islet and consist predominately of the same cell types as
in stage III, as well as infiltrating BM8
+ cells in islets. Stage
IV lesions are characterized by a massive infiltration of
BM8
+ cells, T cells, and B cells. In addition, insulin-
positive β-cell numbers are decreased. In stage VI lesions,
no β-cells are detectable, and few glucagon-positive α-cells
are seen, similar to the insulitis observed in fulminant T1D
[34]. Immune cells are still present in varying numbers in
some islets and other large islets can be found without any
β-cells or immune cells [43].
The earliest pathologic evidence of insulitis in humans
comes from two nondiabetic individuals (ICA
+ GADA
+
IA2A
+) in whom a small number of infiltrates were found
with predominately CD8
+ and CD68
+ cells, as well as
fewer numbers of CD20
+ cells [40]( T a b l e5). This
composition of immune cells corresponds to a stage III
lesion in NOD mice [43], a much later “early” phase of
insulitis, due to the presence of both CD8
+ T cells and
CD68
+ macrophages as well as the peri- and central-
architecture of the infiltrates. Following disease onset, the
variety of islets, in terms of insulin area, examined in the 29
recent-onset cases [96] likely represent stage III, IV, V, and
VI lesions in NOD mice where stage III corresponds to an
islet with 50–69 or 30–49% insulin area, stage IV to an islet
with 10–29% insulin area, stage V to an islet with >0–9%
islet area, and stage VI to an islet with no detectable insulin
area. One obvious difference between insulitis in the NOD
mouse and humans is the greater size of insulitis area
relative to islet area [8].
β-cell hyperplasia/hypertrophy and attraction
of antigen presenting cells
Could the reported larger islets observed in recent-onset
T1D patients, due either to β-cell hyperplasia or hypertro-
phy, be evidence of a process that starts long before disease
onset and culminates with autoimmunity and β-cell
destruction? Although this chapter is focused on character-
ization of the human pathology of T1D, a body of literature
in the NOD mouse describes a number of observations
prior to onset that may parallel some of the human findings
seen after onset. As it's possible to longitudinally follow
islet changes in NOD mice that occur prior to disease onset,
these studies draw attention to a relationship between the
progressive change in islet morphology and the initiation of
insulitis. From birth there are twice as many very small
islets in female NOD and NOD-severe combined immuno-
deficient (scid) mice, compared with C57BL/6 mice [72].
Glucagon area in these very small islets is significantly
greater in NOD mice, with a trend in NODscids, compared
with C57BL/6 mice, a feature that could be indicative of
immature islets [64]. This resembles the large numbers of
small and medium-sized islets observed in an autoantibody-
positive nondiabetic donor [31]. Gepts also described what
appeared to be new islet formation in many recent-onset
cases but not in pancreata from long duration or control
cases [28]. This is suggestive of an adaptive response to
meet metabolic demand that may be caused by β-cell
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[27], early in life [55, 67]). By 4 weeks of age, around the
time of weaning, there are greater numbers of ER-MP23
+
dendritic-like cells and MOMA-1
+ macrophages within and
near to vessels bordering islets in NODs compared to
C57BL/6 mice [43]. Strangely, at 6 weeks of age, “mega-
islets” are seen in NOD and, to a lesser extent, NODscid
mice with APCs primarily found around these large islets
[78]. Since both NOD and NODscid mice had larger islets,
this may be suggestive of an adaptive response to β-cell
dysfunction, rather than insulitis, as β-cell and islet
hypertrophy has been reported in transgenic mice with
impaired glucose-stimulated insulin secretion [58]. Follow-
ing prophylactic insulin treatment, however, the number of
large islets at 6 weeks of age was significantly decreased in
both NOD and NODscid mice [78]. By 9 weeks of age,
51% of the islets in untreated female NOD mice are greater
than 10 μm
2 in size, compared to 9% in BALB/c mice [44].
Following prophylactic insulin treatment, the percentage of
large islets (>10 μm
2) in NOD mice was reduced to the
prevalence found in BALB/c mice at 9 weeks of age [44].
Additionally, while the degree of invasive insulitis was
similar at 9 weeks between mice that did and did not
receive insulin, the numbers of peri-islet ER-MP23
+
dendritic-like cells were significantly reduced in insulin-
treated mice. This effect translated into significantly less
infiltrative insulitis (42%) in the insulin-treated mice
compared to the placebo-treated mice (75%) at 13 weeks
[44]. These studies in NOD mice may be describing a
similar phenomenon to that which gives rise to large islets
Table 5 Comparison of insulitis in human and NOD mouse. Progression of insulitis lesion in the non-obese diabetic (NOD) mouse [43] and in
islet autoantibody-positive nondiabetic (pre-onset) [31, 40] and recent-onset patients with type 1 diabetes [12, 96]
Non-obese diabetic mouse Human
References [43] References [12, 31, 40, 96]
Event Stage(age) Event Stage
Swelling of vessels adjacent to islets Stage I
(3 weeks)
1. No insulitis Pre-onset (IA-2A
+); 1 case
2. Fibrotic areas
3. Large numbers of small, medium islets
associated with ducts
1. Increased numbers ER-MP23+ dendritic-like cells,
MOMA-1+ macrophages, BM8+ macrophages
near islet periphery close to vessels
Stage II
(7 weeks)
1. Infiltrate in 3 & 9% islets Pre-onset (ICA
+, GADA
+,
IA-2A
+); 2 cases
2. Some islets with infiltrating BM8+ macrophages
(females only)
2. Primarily CD8
+, CD68
+
3. Fewer CD20
+, CD4
+
1. Lymphocytes (CD4
+, CD8
+) become detectable
at islet periphery close to vessels
Stage III
(10weeks)
1. Cytotoxic/suppressor T cells, lesser #s
helper T cells, NK cells
Recent-onset (<24 hours
duration); 1 case
2. Most contain B-cells. ER-MP23+, BM8+ cells
among lymphocytes. MOMA-1+ cells at outer
border of lymphocyte accumulation
2. HLA-DR+T cells
3. Islet HLA class I expression
1. Same as above with dendritic cells, macrophages,
lymphocytes completely surrounding islets
Stage IV
(17weeks)
1. CD8>CD20>CD68>CD4
+ cells Recent-onset (<18 months
duration); 29 cases
2. BM8+ cells infiltrating islets (females)
2. Greater numbers of CD8
+, CD20
+ cells
as insulin area decreases
1. Massive infiltration of BM8+, T cells, B-cells Stage V
(17weeks) 2. Few insulin+cells detectable
1. Insulin+cells not detectable Stage VI
2. Few glucagon+cells
3. Varied numbers of all types of lymphocytes and
macrophages
4. Few large insulin-negative islets without any
immune cells.
Semin Immunopathol (2011) 33:29–43 39in T1D patients during early stages, when insulitis is most
aggressive, but not after years of insulin therapy when
insulitis is rarely seen.
Conclusions
Despite the lack of human data related to alterations in islet
morphology prior to T1D onset, In't Veld et al. reported
findings wherein islets with high numbers of Ki-67
+ β-
cells, some of which were affected by insulitis, in a single
autoantibody-positive nondiabetic case [40]. In addition,
unpublished data from the Network for Pancreatic Organ
Donors with Diabetes (nPOD) effort found high numbers of
Ki-67
+ islet cells including β-cells in islets unaffected by
insulitis from a single autoantibody-positive nondiabetic
case (Campbell-Thompson et al., personal communication).
These very limited studies in humans suggest the possibility
that β-cell proliferation may occur prior to insulitis in
individuals genetically susceptible to T1D. It is clearly
difficult to identify factors, genetic and/or environmental,
that may promote β-cell proliferation and recognize when
they occur (before or after β-cell autoimmunity is initiated)
in human T1D cases. Studies in NOD mice, however, may
offer the best alternative to uncover the potential relation-
ship between islet/β-cell function, β-cell adaptive
responses, and environmental factors that further burden
this interaction and initiate autoimmune responses.
Insulitis is commonly observed in new-onset patients,
but it does not uniformly affect all insulin-containing islets
(18–34% [21, 22, 96]). If early stages in the development of
T1D alter islet size/function, prompted by unknown factors,
this non-uniform distribution maybe best explained by
differences in islet function (i.e., glucose sensitivity, Ca
2+
elevation, oxygen consumption, insulin release) if the in
vitro heterogeneity [2, 36] is any reflection of the in vivo
environment. Small islets, for example, isolated from
humans [53] and rats [60] are superior to large islets in
terms of their resistance to cell death in vitro, as well as
insulin secretion when transplanted. This suggests that
under increased insulin demand, such as that which occurs
during puberty/adolescence [81], or high intake of sugars
[73], a population of islets may be more prone to
dysfunction or death, thereby attracting APCs [40, 78, 96]
and promoting insulitis in genetically susceptible individuals.
AlthoughdifficulttotranslatetotheinvivoT1Denvironment,
functional differences may explain the apparent preference of
autoreactive lymphocytes for certain islets.
The best means to identify the factor(s) responsible for
stimulating lymphocyte trafficking to and the destruction of
β-cells, as well as the specific antigens that drive this
process, is still very much a matter of debate. Clearly,
earlier studies have paved the way for such new endeavors,
yet there remains an overwhelming need for novel
strategies that will reveal the nature of early events in
T1D progression. The JDRF-funded nPOD [9] program
was started to address these issues through analysis of
human pancreata obtained from nondiabetic individuals
with islet autoantibody positivity and recent-onset T1D. In
addition, examination of pancreata from cases with gesta-
tional diabetes or post-transplant pancreatic transplantation
for T1D will provide additional critical information
regarding β-cell regenerative capacity in different clinical
settings. Furthermore, efforts like the Type 1 Diabetes
Genetics Consortium [45] are expected to lead to the
identification of additional genes including possibly those
outside the MHC locus. Discovery of genes related to β-
cell function could explain how environmental factors, as
opposed to high-risk HLA, could play a greater role in T1D
incidence in recent years [11, 24]. Ideally, information from
projects such as these will clarify the complex interaction
between autoimmunity, environment, and host genome that
combine to present the clinical heterogeneity seen in T1D.
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